Article Text

Download PDFPDF

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
  1. Jenette Creaney1,2,
  2. Deborah Yeoman1,
  3. Leanne K Naumoff1,
  4. Michelle Hof1,2,
  5. Amanda Segal3,
  6. Arthur William Musk1,4,
  7. Nicholas De Klerk1,5,
  8. Nora Horick,
  9. Steven J Skates,
  10. Bruce W S Robinson1,2
  1. 1National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Australia
  2. 2Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Perth, Australia
  3. 3PathWest Laboratory Medicine WA, Queen Elizabeth II Medical Centre, Perth, Australia
  4. 4Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia
  5. 5Telethon Institute of Child Health Research, Subiaco, AustraliaBiostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to:
    Dr Jenette Creaney
    Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands, 6009, Western Australia, Australia; creaneyj{at}


Background: The diagnosis of malignant mesothelioma is frequently difficult, the most common differential diagnosis being reactive pleural conditions and metastatic adenocarcinoma. Soluble mesothelin levels in serum have recently been shown to be highly specific and moderately sensitive for mesothelioma. As most patients with mesothelioma present with exudative effusions of either the pleura or the peritoneum, a study was undertaken to determine if levels of mesothelin were raised in these fluids and if the increased levels could help to distinguish mesothelioma from other causes of exudative effusion.

Methods: Pleural fluid was collected from 192 patients who presented to respiratory clinics (52 with malignant mesothelioma, 56 with non-mesotheliomatous malignancies and 84 with effusions of non-neoplastic origin). Peritoneal fluid was collected from 42 patients (7 with mesothelioma, 14 with non-mesotheliomatous malignancies and 21 with benign effusions). Mesothelin levels were determined in effusion and serum samples by ELISA.

Results: Significantly higher levels of mesothelin were found in effusions of patients with mesothelioma; with a specificity of 98%, the assay had a sensitivity of 67% comparing patients with mesothelioma and those with effusions of non-neoplastic origin. In 7 out of 10 cases mesothelin levels were raised in the effusion collected 3 weeks to 10 months before the diagnosis of mesothelioma was made; in 4 out of 8 of these, mesothelin levels were increased in the effusion but not in the serum.

Conclusions: Measurement of mesothelin concentrations in the pleural and/or peritoneal effusion of patients may aid in the differential diagnosis of mesothelioma in patients presenting with effusions.

  • CA, cancer antigen
  • CEA, carcinoembryonic antigen
  • CYFRA, cytokine fragment
  • ROC, receiver operating characteristic
View Full Text

Statistics from


  • Published Online First 13 March 2007

  • Supported in part by research grants from the National Health and Medical Research Council of Australia and the Insurance Commission of Western Australia, the Raine Foundation, and in part by Fujirebio Diagnositic Malvern, Pennsylvania, USA. Biospecimens were provided by members of the ABN-Oncology Group which is funded by the National Health and Medical Research Council of Australia.

  • JC and BWR have received consultancy fees from FDI. The remaining authors have no conflicts of interest to disclose.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles